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Abstract 24 
The inhibitory quotient (IQ) of human immunodeficiency virus (HIV) protease inhibitors 25 
(PI) that is the ratio of drug concentration to viral susceptibility is considered to be 26 
predictive of the virological response. We used several approaches to calculate the IQs of 27 
amprenavir and lopinavir in a subset of heavily pretreated patients participating in the 28 
ANRS-104 trial, then compared their potential for predicting changes in the plasma HIV-29 
RNA level. Thirty-seven patients were randomly assigned to receive either amprenavir 30 
(600mg BID) or lopinavir (400mg BID) plus ritonavir (100 or 200mg BID) for two 31 
weeks, before combining the two PIs. The IC90 was measured using a recombinant assay 32 
with or without additional human serum (IC90+serum). Total and unbound PIs 33 
concentrations in plasma were measured. Univariate linear regression was used to 34 
estimate the relation between the change in viral load and the IC90 or IQ values. The 35 
amprenavir phenotypic IQ values were very similar when measured with the standard 36 
and protein binding-adjusted IC90. No relationship was found between the viral load 37 
decline and the lopinavir IQ. During combination therapy the amprenavir and lopinavir 38 
genotypic IQ values were predictive of the viral response at week 6 (p=0.03). The 39 
number of protease mutations (< or ≥5) was related to the virological response 40 
throughout the study. These findings suggest that the combined genotypic IQ and the 41 
number of protease mutations are the best predictors of virological response. High 42 
amprenavir and lopinavir concentrations in these patients might explain why plasma 43 
concentrations and the phenotypic IQ have poor predictive value. 44 
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Introduction 45 
The virological efficacy of protease inhibitors (PI) in patients infected by the Human 46 
Immunodeficiency Virus (HIV) is dependent on both their pharmacodynamic and 47 
pharmacokinetic properties. In vitro high and sustained plasma (or cell) concentrations are 48 
needed to maximally suppress viral replication. The dose administered in HIV-infected patients 49 
should provide such concentrations. 50 
The inhibitory quotient (IQ), defined as the ratio of the trough drug concentration to viral 51 
susceptibility expressed as an inhibitory concentration (ideally the IC90), has been used to 52 
estimate the antiviral potency of PIs in vivo (24). This parameter has also been proposed to 53 
optimize the dosing regimen of treatment-experienced patients (12, 20). Although there is a 54 
strong theoretical rationale for using the inhibitory quotient, the practical value of this parameter 55 
is controversial. Firstly, there are few prospective studies of the relationship between IQ and 56 
virological response (22). Secondly, there is no consensus method for calculating this parameter 57 
(1, 24, 27). Standard calculations estimate IQ from both the plasma drug concentration and virus 58 
susceptibility. However, several pharmacokinetic and virologic issues remain unsolved. In most 59 
pharmacokinetic studies the total drug concentration in plasma is measured, whereas the active 60 
component is the free (protein-unbound) fraction. Furthermore, the addition of human albumin to 61 
the cell culture medium increases the IC90 in vitro. In summary, either the total concentration or 62 
the protein-adjusted concentration, and either the standard or the serum-adjusted IC90, can be used 63 
to calculate the IQ. More recently, a “genotypic inhibitory quotient” was proposed, as the ratio of 64 
the plasma concentration to the number of mutations on the viral protease gene. Indeed, 65 
genotypic resistance assays can be performed rapidly and are less costly than phenotypic 66 
resistance assays (11). Both genotypic and phenotypic IQs are predictive of changes in the HIV 67 
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RNA level in treatment-experienced patients (5, 9, 11, 17, 22, 23, 31), but only one study of the 68 
predictive value of the IQ is available in patients treated with two ritonavir-boosted PIs (8). 69 
We aimed at estimating the relationship between IQs of amprenavir and lopinavir and virological 70 
response after 2, 6 and 26 weeks of treatment in a group of heavily pretreated patients who 71 
participated in the ANRS-104 trial. Several methods for calculating IQs were compared with the 72 
viral phenotype and genotype for their ability to predict changes in plasma viral load. 73 
Materials and methods 74 
Study design and study population 75 
The ANRS 104 study was a prospective, randomized, open-label, multicenter trial involving 76 
patients with CD4 < 500/mm3 and plasma HIV RNA > 10 000 copies/mL after receiving 77 
successive antiretroviral treatments including at least two PIs and one non nucleoside reverse 78 
transcriptase inhibitor (NNRTI). The main objective of this trial was to compare the clinical 79 
efficacy and tolerability of a combination of amprenavir and lopinavir/ritonavir in treatment-80 
experienced patients (26). The study was divided into two periods. For the first two weeks 81 
(period 1), patients were randomized to receive, in addition to their ongoing nucleoside reverse 82 
transcriptase inhibitors (NRTI), 1) lopinavir/ritonavir (400/100mg BID) or lopinavir/ritonavir 83 
(400/100 mg BID) + ritonavir (100 mg BID), 2) amprenavir (600 mg BID) + ritonavir (100 mg 84 
BID), or amprenavir (600 mg BID) + ritonavir (200 mg BID). From week 3 to week 26 (period 85 
2), all the patients received amprenavir + lopinavir/ritonavir, with or without an additional boost 86 
of ritonavir 100 mg BID. The NRTIs were optimized on the basis of viral genotyping results and 87 
previous antiretroviral exposure. The genotype was interpreted for each inhibitor by using the 88 
2001 update of the French National Agency for AIDS Research (ANRS) algorithm. Patients were 89 
recruited from 16 French clinical AIDS units. All patients signed an Ethics Committee-approved 90 
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informed consent form. Patients were instructed to take their medication in the morning and 91 
evening, with a light meal. Physical examinations, CD4 and CD8 cell counts, hematologic and 92 
clinical chemistry measurements were performed at each study visit (weeks -2, 0, 2, 4 and 6, then 93 
monthly for the subsequent 20 weeks). Blood samples were also drawn, at weeks –2, 0, 2, 6, and 94 
26, for plasma HIV-1 RNA, viral genotyping and phenotyping and drug assays in plasma. 95 
 96 
Laboratory measurements 97 
Virological parameters 98 
Plasma HIV-1 RNA was assayed locally at weeks –2, 0, 2, 4, 6, 14 and 26, by using the Roche 99 
Amplicor HIV-1 Monitor kit (Roche, France; limit of quantitation (LOQ) 200 copies/mL) or the 100 
Quantiplex® HIV-RNA 3.0 assay (Bayer diagnostics, France; LOQ 50 copies/mL).  101 
HIV-1 protease genotyping and phenotyping 102 
Viral genotyping was performed at weeks -2, 2, 6 and 26, based on direct sequencing of the HIV-103 
1 protease coding region, using the consensus technique of the ANRS AC11 Resistance Group or 104 
the TruGene HIV-1 genotyping kit (Visible Genetics, Bayer). The genotype was taken into 105 
account only if a complete protease sequence (amino acids 1-99) was obtained. Protease 106 
sequences from each patient were examined for the presence of mutations associated with 107 
protease resistance at 21 relevant codons (11): 10, 20, 24, 30, 32, 33, 36, 46, 47, 48, 50, 53, 54, 108 
63, 71, 73, 77, 82, 84, 88 and 90 (The Stanford HIV drug resistance database, 2004. 109 
http://hivdb.stanford.edu/). The genotype for lopinavir/ritonavir and amprenavir/ritonavir was 110 
interpreted by using the 2006 update of the French National Agency for AIDS Research (ANRS) 111 
algorithm.  112 
Resistance phenotyping was performed at screening (week-2) in all the patients and at week 26 in 113 
those patients who failed drug regimen and had plasma HIV-RNA above 50 copies/mL (20/37 114 
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patients), using a recombinant virus assay (PhenoscriptR, Viralliance) (25). Results were 115 
expressed as the PI concentration inhibiting virus spread by 90% (IC90), in a standard method 116 
without added human serum (IC90). In a subgroup of 12 patients who started their study regimen 117 
with amprenavir, the amprenavir IC90 was also determined after adding 40% human serum to the 118 
growth medium which contains 10% fetal bovine serum in order to reach a total protein 119 
concentration close to that found in human plasma (IC90+serum).  120 
Drug assays in plasma 121 
Blood samples were drawn at week 2 and week 6, just before the scheduled drug intake (Cmin). 122 
The total and unbound amprenavir and total lopinavir Cmin values were measured by HPLC with 123 
separation on a C18 column after liquid/liquid extraction of alkaline plasma and UV detection as 124 
described elsewhere (2, 26, 29). Bound and unbound amprenavir were separated by ultrafiltration 125 
using Centrifree devices (Amicon, YM-300 filter system, Millipore Corp., Bedford, 126 
Massachussets, USA). Amprenavir was then measured in the ultrafiltrate as previously described. 127 
The overall day-do-day coefficient of variation was below 12 % (2). All concentrations were 128 
expressed in ng/mL or µmol/L for inhibitory quotient calculations. 129 
Calculation of IQs 130 
Phenotypic IQs were calculated as the ratio of the plasma Cmin of each PI to the IC90 measured at 131 
baseline. For amprenavir, the IC90 values were determined with or without added protein 132 
(IC90+serum or IC90), and both the total and unbound Cmin (Cminu) values were measured. Two 133 
methods to adjust for protein binding were tested, namely the Cminu and the IC90+serum (24). 134 
Amprenavir IQs were therefore calculated as the ratios of Cminu/IC90 (IQu) and Cmin/IC90+serum 135 
(IQserum).  136 
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The genotypic inhibitory quotient (GIQ) of each PI was calculated as the ratio of the plasma 137 
Cmin corrected for protein binding (Cminu) to the baseline number of protease resistance 138 
mutations. The following mutations on the viral protease were considered: L10I/F/R/V, K20M/R, 139 
L24I, D30N, V32I, L33F, M36I, M46I/L, I47A/V, G48V, I50V, F53L, I54L/T/V, L63P, 140 
A71I/L/V/T, G73S, V77I, V82A/F/T/S, A84V, N88D/S, and L90M. 141 
During the second treatment period, in which patients received two ritonavir-boosted PIs, the 142 
combined IQs were calculated as the sum of the phenotypic IQu for each PI. Cminu was not 143 
measured but was calculated as the total Cmin corrected by the average protein binding of 144 
amprenavir (10%) (2, 15) and lopinavir and ritonavir (1%) (3, 4). The genotypic combined IQ 145 
was calculated as the sum of the ratios of Cminu/number of protease resistance mutations.  146 
 147 
Statistical analysis 148 
The median (range) was used to describe the distribution of amprenavir, lopinavir and ritonavir 149 
parameters and for the different IQ calculations. Univariate linear regression was used to estimate 150 
the relation between the decline in viral load (difference between baseline and weeks 2, 6 or 26) 151 
and the different Cmin, IC90 and IQ values. The higher the proportion of explained variance (r2) 152 
of viral load, the better the model. All statistical tests were run on SAS software (version 8.2; 153 
SAS Institute). 154 
Results 155 
Overall, 37 patients were enrolled in the ANRS 104 study. Their baseline characteristics are 156 
shown in table 1. Twenty three patients started their study antiretroviral drug regimen with 157 
lopinavir/ritonavir (group 1) and 14 patients started with amprenavir (group 2) .  158 
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Amprenavir and lopinavir Cmin values are reported in detail elsewhere (26, 29) and were not 159 
related to the virologic response. The median unbound amprenavir Cminu at week 2 was 177 160 
ng/mL and was not predictive of the virologic response at week 2.  161 
In a subgroup of 12 patients who had phenotypic studies (group 2), the amprenavir IC90 was 57.8 162 
ng/mL (8.7-150.9), and increased to 453 ng/mL (33-1105) when measured in the presence of 163 
50% human serum (IC90+serum). The IC90+serum was a good predictor of the early virologic response 164 
(w2 p=0.006), whereas the IC90 was not. Amprenavir IQs adjusted for protein binding (IQu and 165 
IQserum) were rather similar (2.5 and 3.6, respectively). The relationship with viral load decline at 166 
week 2 was slightly better with IQu than IQserum (r2=0.45, p=0.02 versus r2=0.31, p=0.06), 167 
although those results might be explained by an outlier patient (r2=0.24, p=0.12 versus r2=0.11, 168 
p=0.31 without the outlier patient).  169 
In the 21 patients treated with lopinavir during the first period, the lopinavir IC90 was 34.2 ng/mL 170 
(0.7-330.4) and was a good predictor of the virologic response at weeks 2, 6 and 26 (r2=0.37, 171 
p=0.003; r2=0.23, p=0.03; r2=0.33, p=0.006 respectively). 172 
The number of protease mutations (< or >5) was related to the virologic response throughout the 173 
study (at week 2, r2=0.18, p=0.008; at week 6 r2=0.11, p=0.046; and at week 26 r2=0.12, p=0.034 174 
- figure 1).  175 
Table 2 shows the virologic responses throughout the study as a function of the amprenavir and 176 
lopinavir phenotypic IQ and GIQ values measured at week 2 or week 6. The amprenavir 177 
genotypic IQ (corrected amprenavir Cmin at week 2/number of protease mutations at week -2) 178 
was related to the virologic response at week 2 (r2=0.66, p=0.0004) and at week 6 (r2=0.38, 179 
p=0.02). Patients who had a Cmin corrected GIQ above 75 had a median decline in HIV-RNA of 180 
1.23 log10 copies/mL (-2.27 ; -0.97) versus 0.19 log10 copies/mL (-1.07 ; 0.15) in patients with a 181 
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GIQ below 75 (p=0.005). In contrast, none of the lopinavir IQs was predictive of antiretroviral 182 
activity.  183 
None of the phenotypic or genotypic IQs of amprenavir or lopinavir (determined with the Cmin 184 
corrected for protein binding and measured at week 6) was predictive of the viral load decline. 185 
However, a combination of the amprenavir and lopinavir genotypic IQs, whether measured either 186 
with the standard equation or adjusted for protein binding, and with or without ritonavir, was 187 
predictive of the viral response at week 6 but not at the end of the study as shown on figure 2. 188 
Patients who responded at week 6 (plasma HIV-RNA < vs ≥ 10000 copies/mL) had a higher 189 
median combined genotypic IQ measured at week 6 (65 vs 29 p=0.01). 190 
Discussion 191 
A significant proportion of antiretroviral-experienced patients never have optimal viral 192 
suppression or experience a viral rebound shortly after starting a new treatment. Our population 193 
was heavily pretreated with a high proportion of baseline NRTIs genotypic resistance, 194 
consequently, the efficacy of the combination results essentially from both PIs. Treatment thus 195 
needs to be optimized according to viral susceptibility and the plasma PI concentration. This 196 
study provides IQ data for two currently used ritonavir-boosted PIs, amprenavir and lopinavir, 197 
when administered alone (first two weeks of the study) or in combination, in heavily pretreated 198 
HIV-infected patients. This is one of the few studies to show that the combined IQ can be a 199 
useful predictor in patients who receive ritonavir-boosted dual-PI therapy (8). 200 
We compared two methods for calculating the phenotypic IQ, which incorporates protein 201 
binding. Amprenavir and lopinavir are highly bound to plasma proteins, and especially alpha1 202 
acid glycoprotein (90% and 98-99% respectively). As only free drug inhibits viral replication, 203 
protein binding affects the potency of these two PIs. ICs measured in vitro must be adjusted for 204 
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protein binding before extrapolation to the clinical setting. Moreover, ICs suffer from variability 205 
due to a lack of standardisation of phenotyping methods (14). There are three methods for 206 
adjusting the in vitro IC for protein binding: multiplication of the IC by the free fraction 207 
measured in vivo; measurement of the IC in the presence of 50% human serum albumin; and 208 
multiplication of the IC by a constant to adjust for assay variations (20), but none of these 209 
methods is clinically validated. Our results show that, whatever the equation used to calculate IQ 210 
(Cminu/standard IC90 or Cmin/IC90+serum), the relationship with viral load decline is very similar. 211 
The best correlation was obtained with the IQu (Cminu/IC90). It has previously been 212 
demonstrated that measuring and calculating the Cminu gives similar results (29). However, it 213 
remains to be determined whether these findings can be extrapolated to PIs other than 214 
amprenavir. 215 
We found no relationship between lopinavir or amprenavir exposure and the decline in viral load, 216 
in agreement with previous studies (6, 7, 13, 16, 30). Amprenavir and lopinavir Cmin values 217 
obtained with the ritonavir boost were far higher than the IC50 reported for wild-type virus (28) 218 
and the IC90 measured at screening. This might explain why plasma concentrations were poorly 219 
predictive of the decline in plasma HIV RNA. Compliance with medication was not measured in 220 
our study; the amprenavir and lopinavir Cmin values suggested that it was maximal at week 2 221 
and week 6 but declined thereafter. Thus, none of the phenotypic IQ values based on 222 
concentrations measured at week 6 was predictive of antiviral efficacy.  223 
The genotypic IQ is simpler to measure than the phenotypic IQ. We found that the genotypic IQ 224 
of amprenavir was associated with the virologic response at week 2 and week 6 but not at week 225 
26. Furthermore the amprenavir GIQ cut off of 75 could be a useful tool in clinical practice as 226 
previously demonstrated by Marcelin et al. (18). Our findings confirm that the genotypic IQ, 227 
which incorporates both baseline viral resistance and the level of drug exposure in plasma, is 228 
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superior to drug exposure alone in predicting the virologic response to a salvage regimen (18). 229 
However, lopinavir IQs did not correlate with virologic efficacy, and our data do not support 230 
those reported elsewhere (5, 9, 16). This is probably because the lopinavir Cmin values in our 231 
patients were sufficiently high not to restrict efficacy (13), whereas lopinavir concentrations were 232 
lower in other studies (5, 9). In these latter studies, the Cmin was determined as part of routine 233 
therapeutic drug monitoring or observational studies, settings in which compliance is important 234 
for overall exposure (5, 9, 16). One limitation of therapeutic drug monitoring is the wide intra-235 
patient variability of trough concentrations, as recently demonstrated by Nettles et al.(21) and 236 
Goujard et al. (10). Poor compliance and an effect of food may be involved in this variability. We 237 
acknowledge that one limitation of our study is that compliance was not measured. However, 238 
comparison of trough concentrations measured at weeks 6, 14 and 26 clearly shows that 239 
compliance is decreasing from week 6, where concentrations of lopinavir and amprenavir were in 240 
the expected range in all patients, in contrast to weeks 14 and 26 where 7 and 6 patients 241 
respectively, had concentrations below the limit of quantification of the assay (26). 242 
Interestingly, the combined GIQ was predictive of the virologic response at week 6, as in the 243 
GigHAART trial (8). This suggests that a combination of two PIs has a strong antiviral effect that 244 
might overcome resistance in these strongly pretreated patients. As expected, ritonavir did not 245 
participate in the drug effect, as the concentrations used to boost PIs are too low (even though 246 
some patients received 200 mg BID). The combined IQ of amprenavir+lopinavir+ritonavir was 247 
close to the combined IQ of amprenavir+lopinavir and had the same predictive potential. 248 
However, the predictive value of this parameter disappeared at the end of the study, for several 249 
possible reasons: in particular, the Cmin tends to fall, as a negative initial interaction between the 250 
two PIs and a decreased compliance tends to reduce their concentrations and exposure levels; 251 
second, the viral resistance profile is continually evolving (19). Further studies are needed to 252 
CCE
PTE
D
 at INSERM
 on M
arch 12, 2008 
a
a
c.a
sm
.o
rg
D
ow
nloaded from
 
H
AL author m
anuscript    inserm
-00263587, version 1
H
AL author m
anuscript    inserm
-00263587, version 1
 12/23 
determine which viral mutations have the biggest impact on the genotypic IQ, and how these 253 
mutations can be taken into account in the calculations (30). 254 
The combined genotypic IQ did not have better predictive value than the number of mutations. In 255 
these highly pretreated patients with high PI Cmin values, the number of PI resistance mutations 256 
is a major determinant of virologic outcome (5, 13, 16) and, in our study, was the only factor 257 
predictive of the virologic response at week 26. Finally, as previously demonstrated (26), patients 258 
with more than five protease resistance mutations or a lopinavir mutation score (13,14) higher 259 
than 5 at baseline had a significantly poorer virological response than other patients (p=0.04 and 260 
p=0.006, respectively). 261 
Thus, this study suggests that when treatment compliance is optimal and high PI concentrations 262 
are achieved, the viral genotype is the best predictor of virologic outcome.  263 
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TABLE 1: Baseline characteristics of the patients participating in the ANRS 104 Study. 401 
Patients from group 1 started with amprenavir/ritonavir for the first 2 weeks and patients 402 
from group 2 started with lopinavir/r 403 
Parameters 
Group 1, amprenavir 
n=14 
Group 2, lopinavir 
n=23 
Median age, years (range) 47 (32-53) 41 (27-65) 
Males, n (%) 12 (86) 21 (91) 
CDC clinical stage,  n (%) n (%) 
A 6 (42) 10 (43) 
B 4 (29) 3 (13) 
C 4 (29) 10 (43) 
Median CD4+ cells/mm3 (range) 195 (65-385) 185 (3-509) 
Median HIV1-RNA, log10 copies/mL (range) 4.9 (3.6-5.7) 4.6 (3.8-5.6) 
Median number of previous antiretrovirals (range) 7.5 (4-12) 7.5 (4-12) 
Median number of antiretrovirals taken prior to 
inclusion and still in use at inclusion (range) 
9.5 (7-13) 10 (8-13) 
Genotypic resistance             n (%) n (%) 
Amprenavir/r 7 (50) 9 (56) 
Lopinavir/r 7 (50) 7 (30) 
Median (range) number of protease mutations  7.0 (1.0-9.0) 7.0 (1.0-10.0) 
Median (range) number of reverse transcriptase 
mutations 
6.5 (0-11.0) 7.0  (0.0-11.0) 
Median (range) phenotypic resistance index  
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Amprenavir 2.8 (0.5-24.3) 2.5 (0.5-19.5) 
Lopinavir 8.7 (0.3-84.0) 10.7 (0.2-95.3) 
 404 
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TABLE 2: Relationships between the viral load decline at weeks 2, 6 and 26 and the 405 
amprenavir, lopinavir and ritonavir inhibitory quotients (univariate analysis) 406 
p 
Inhibitory quotients Week 
Number of 
patients  
Median (min-max) 
Week 2 Week 6 Week 26 
2 13 4.3 (0.62-25.9) 0.04 0.24 0.70 
IQsd 
6 13 1.8 (0.20-11.7)  0.80 0.26 
2 14 81.2 (17.9-291.1) 0.0004 0.02 0.16 
Amprenavir 
GIQ 
6 14 26.4 (9.8-69.1)  0.56 0.59 
2 21 4.0 (0.16-153.3) 0.97 0.65 0.66 
IQsd 
6 21 2.0 (0.15-157.5)  0.70 0.80 
2 23 23.9 (6.6-177.6) 0.37 0.20 0.20 
Lopinavir 
GIQ 
6 23 17.8 (3.6-182.5)  0.15 0.36 
2 34 0.01 (0.0004-0.5) 0.55 0.18 0.28 
IQsd 
6 34 0.005 (0.0004-0.8)  0.34 0.87 
2 37 1.7 (0.12-19.1) 0.18 0.10 0.12 
Ritonavir 
GIQ 
6 37 1.3 (0.12-20.4)  0.16 0.45 
IQsd 6 34 4.9 (0.36-166.5)  0.34 0.71 Amprenavir+ 
Lopinavir GIQ 6 37 46.9 (15.9-543.4)  0.03 0.15 
IQsd 6 34 4.9 (0.37-167.3)  0.34 0.71 Amprenavir+ 
Lopinavir+ 
Ritonavir 
GIQ 6 37 48.8 (16.0-549.3)  0.03 0.15 
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IQsd: standard inhibitory quotient: trough concentration (Cmin) at week 2 or 6/IC90 standard at 407 
week -2, GIQ: genotypic inhibitory quotient: corrected Cmin (calculated protein unbound Cminu) 408 
at week 2 or 6/number of protease mutations at week –2.  409 
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 Figure 1: relationship between viral load decline at week 26 and the number of protease 1 
mutations at screening (r2 0.13, p=0.03).  2 
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Figure 2: relationship between viral load decline at week 6 and combined (lopinavir and 1 
amprenavir) genotypic inhibitory quotient at week 6 (r2= 0.12, p=0.03).  2 
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